ClinicalTrials.gov
ClinicalTrials.gov Menu

Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02062073
Recruitment Status : Completed
First Posted : February 13, 2014
Last Update Posted : March 16, 2016
Sponsor:
Collaborators:
TKL Research, Inc.
Accelovance
Information provided by (Responsible Party):
Hatchtech Pty Ltd

Brief Summary:
Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.

Condition or disease Intervention/treatment Phase
Head Lice Drug: Abametapir Lotion 0.74% w/w Other: 0.1% sodium lauryl sulfate Other: saline 0.9% Other: Vehicle Lotion Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 238 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Abametapir Lotion in Healthy Volunteers Using a Repeat Insult Patch Test Design
Study Start Date : January 2014
Actual Primary Completion Date : March 2014
Actual Study Completion Date : June 2014

Arm Intervention/treatment
Active Comparator: Abametapir Lotion 0.74%
0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
Drug: Abametapir Lotion 0.74% w/w
Placebo Comparator: Vehicle Lotion
0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
Other: Vehicle Lotion
0.1% sodium lauryl sulfate
Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
Other: 0.1% sodium lauryl sulfate
Saline 0.9%
Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
Other: saline 0.9%



Primary Outcome Measures :
  1. to evaluate the sensitizing potential of abametapir lotion using repeat insult patch test design [ Time Frame: 8 weeks ]
    Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Are healthy (to be confirmed by medical history) males or females, 18 years of age or older;
  2. In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomized partner are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
  3. If female of childbearing potential, have a negative urine pregnancy test at Day 1, and are willing to submit to a pregnancy test at the end of study;
  4. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
  5. Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
  6. Complete a patch study Medical Screening form as well as a Medical Personal History form; and
  7. Read, understand, and provide signed informed consent.

Exclusion Criteria:

  1. Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
  2. Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
  3. Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
  4. Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
  5. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
  6. Have psoriasis and/or active atopic dermatitis/eczema;
  7. Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
  8. Have a known sensitivity to constituents present in the material being evaluated;
  9. Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
  10. Have received treatment for any type of internal cancer within 5 years prior to study entry;
  11. Have a history of, or are currently being treated for skin cancer;
  12. Are currently participating in any other clinical trial;
  13. Have any known sensitivity to adhesives; and/or
  14. Have received any investigational treatment(s) within 4 weeks prior to study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02062073


Locations
United States, New Jersey
TKL Reserach
Paramus, New Jersey, United States, 07652
Sponsors and Collaborators
Hatchtech Pty Ltd
TKL Research, Inc.
Accelovance

Responsible Party: Hatchtech Pty Ltd
ClinicalTrials.gov Identifier: NCT02062073     History of Changes
Other Study ID Numbers: Ha03-006
First Posted: February 13, 2014    Key Record Dates
Last Update Posted: March 16, 2016
Last Verified: March 2016

Keywords provided by Hatchtech Pty Ltd:
head lice
Hatchtech